NCT07512674 2026-04-06
Modified Short-Course Radiotherapy Combined With Immunochemotherapy and Targeted Therapy as First-Line Treatment for MSS Metastatic Colorectal Cancer
Sir Run Run Shaw Hospital
Phase 2 Active not recruiting
Clinical Trials
22 trialsNCT05984602 2026-03-30
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
NYU Langone Health
Phase 1 Active not recruiting
NCT04387084 2026-03-23
Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy
University of Southern California
Phase 1 Active not recruiting
NCT05502250 2026-03-06
HOVON164HL
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 2 Active not recruiting
NCT06356597 2026-02-24
Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial
Shanghai Jiao Tong University School of Medicine
Phase 2 Active not recruiting
NCT05189457 2025-12-04
First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT06866548 2025-12-04
Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
Shanghai Changzheng Hospital
Phase EARLY_PHASE1 Active not recruiting
NCT06139419 2025-11-17
The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC
Sun Yat-sen University
Phase 2 Active not recruiting
NCT06124378 2025-09-24
Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer
First Affiliated Hospital of Guangxi Medical University
Phase 2 Active not recruiting
NCT05604560 2025-07-23
A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer
The University of Texas Health Science Center at San Antonio
Phase 2 Active not recruiting
NCT06939439 2025-07-01
Using ctDNA to Guide Treatment Decisions for Stage III Gastric Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 3 Active not recruiting
NCT05319574 2025-06-12
SACTION01
Sun Yat-sen University
Phase 2 Active not recruiting
NCT06009861 2025-06-06
Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)
Peking University Hospital of Stomatology
Phase 2 Active not recruiting
NCT06056804 2025-04-02
Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer
Beijing Friendship Hospital
Phase 2 Active not recruiting
NCT04802876 2025-03-21
ACROPOLI
SOLTI Breast Cancer Research Group
Phase 2 Active not recruiting
NCT05586061 2025-02-07
RCTS
Qilu Hospital of Shandong University
Phase 2 Active not recruiting
NCT06239532 2024-11-21
HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma
Qilu Hospital of Shandong University
Phase 2 Active not recruiting
NCT05520619 2024-11-18
EC-CRT-002
Sun Yat-sen University
Phase 2 Active not recruiting
NCT05724329 2024-09-19
Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Active not recruiting
NCT04727996 2024-04-19
BTC-BGB
Seoul National University Hospital
Phase 2 Active not recruiting
NCT05211232 2024-04-18
Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Active not recruiting
NCT04776590 2024-04-12
CRISEC
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Active not recruiting